Effect of Panel-Reactive Antibody on Graft Survival in Living Kidney Donor Transplantation: Analysis of 10 Years in a Transplant Center in Veracruz, Mexico

Martínez-Mier, Gustavo; Vazquez-Crespo, Luis Vicente; Angeles-Hernández, Fausto; Viñas-Dozal, Julio Cesar; Moreno-Ley, Pedro Iván; Budar-Fernández, Luis F; Méndez-López, Marco T; Allende-Castellanos, Carlos A.; Jiménez-López, Luis Alfredo; Bonilla-Casas, Elias; Paz-Román, Maritza De la; Fuentes-Zamudio, Einar Eduardo

doi:10.1016/j.transproceed.2020.01.060

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Meanwhile, PRA is closely related to rejection and graft survival in renal transplants. 24,25 Opelz et al 26 reported that 10-year graft survival was lower in recipients with PRA > 50% than in recipients with 0% PRA. Von Moos et al 27 found that PRA was associated with medium-term graft dysfunction compared with recipients without PRA in a follow-up visit.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Iguratimod reduces panel reactive antibody in high mismatched renal transplant recipients: One single‐center experience

Feng

Huang

Chen

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy and safety of iguratimod (IGU) for reducing panel reactive antibody (PRA) in high-mismatched renal transplant recipients. Methods:Eligible recipients positive for PRAs who received or did not receive IGU treatment were enrolled. We retrospectively reviewed, collected, and analyzed statistically the clinical data of the recipients.Results: A total of 80 recipients were included for further analysis. After IGU was administered for 9 months, no significant difference was found in the change rates of donor specific antibodies between two groups. Meanwhile, the reduction in the PRAs in the IGU group was greater than that in the non-IGU group in anti-human leukocyte antigen (HLA) class I and class II, anti-HLA class I, anti-HLA class II, anti-HLA A, and anti-HLA DR antibodies. However, no differences were found in the anti-HLA B, anti-HLA Cw, anti-HLA DP, and anti-HLA DQ antibodies between the two groups.No serious adverse events were reported, and the incidence of adverse events was comparable between the two groups. Conclusion:PRA levels in high-mismatched renal transplant recipients were significantly reduced after the administration of IGU. The high safety of IGU was also determined.

show abstract

Section: Discussionmentioning

confidence: 99%

“…DSA, including preexisting DSA and de novo DSA, emerges before and after renal transplantation and is a critical component for diagnosing ABMR 23 . Meanwhile, PRA is closely related to rejection and graft survival in renal transplants 24,25 . Opelz et al 26 .…”

Section: Discussionmentioning

confidence: 99%